STAT+: Radiopharma companies merge after one receives surprise FDA rejection

STAT PlusPharma Radiopharma companies merge after one receives surprise FDA rejection ITM Isotope Technologies to acquire Telix Pharmaceuticals in deal worth at least $1.65B Manage alerts for this article Save this story for later Share this article By Allison DeAngelisSept. 20, 2026 Biotech Startups and Venture Capital Reporter Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.

ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging in a deal worth at least $1.65 billion. Under the deal, Telix will acquire all shares of the privately held company ITM. Telix could also pay another $700 million to shareholders, if ITM’s lead drug meets regulatory and sales goals.Advertisement The merger creates another well-resourced company in the radiopharmaceutical field, which is currently dominated by Novartis.

These medicines work by delivering radioactive isotopes directly to cancer cells. Novartis supercharged the field with the launch of its two such treatments in 2018 and 2022. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Cancer, Pharmaceuticals, STAT+ Submit a correction requestReprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them.

She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout September 18, 2026 STAT Plus: Roche expands its Boston footprint with new research center Biotech September 17, 2026 STAT Plus: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease Advertisement The Readout September 17, 2026 STAT Plus: New startup to test psychedelic-like drug against Parkinson’s symptom Adam's Biotech Scorecard September 17, 2026 STAT Plus: A Sellas immunotherapy study, long delayed, will end in failure Adam's Biotech Scorecard September 17, 2026 STAT Plus: A biotech hedge fund births a new immunology company Subscriber Picks